USPTO Patent Grant for Low Dose Therapeutic Treatment
Summary
The USPTO has granted patent US12582666B2 to Syqe Medical Ltd. for a low dose therapeutic treatment system. The patent covers a system for delivering predetermined amounts of THC, with specific limits on dosage and delivery time, utilizing a decision module and an inhaler device.
What changed
The United States Patent and Trademark Office (USPTO) has issued patent US12582666B2 to Syqe Medical Ltd. This patent pertains to a system designed for the controlled delivery of THC, specifically limiting the maximum amount of THC delivered to 0.75 mg or less within a 2-hour period or longer. The system incorporates a memory storing a scheduled regimen, a decision module to determine delivery timing, and an inhaler device with a controller to execute the delivery.
While patent grants are not direct regulations, they establish intellectual property rights that can influence market entry and product development. Companies operating in the therapeutic use of cannabinoids should be aware of this patent, as it may impact their ability to develop or market similar low-dose THC delivery systems. No immediate compliance actions are required for regulated entities, but this patent may necessitate review of product development strategies and potential licensing considerations.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Low dose therapeutic treatment
Grant US12582666B2 Kind: B2 Mar 24, 2026
Assignee
Syqe Medical Ltd.
Inventors
Perry Davidson, Seth Kindler, Shlomo Almog, Binyamin Schwartz, Aaron Schorr, Daniella Atzmony
Abstract
Some embodiments of the invention relate to a system for delivering to a subject at least one pre-determined amount of THC, the system comprising: a memory which stores a scheduled regimen for delivery of THC to the subject, the scheduled regimen defining: a maximal amount of THC to be delivered, the amount being 0.75 mg THC or less, and a time period within which that amount is delivered, the time period being 2 hours or longer; a decision module which decides, according to the scheduled regimen, if a delivery should take place; and an inhaler device for delivering THC to the subject, the inhaler device comprising a controller which carries out delivery of THC based on the decision made by the decision module.
CPC Classifications
A61M 15/00-0013 A61M 15/0028 A61M 15/0065-0078 A61M 15/0085 A61M 15/009-0098 A61M 15/06 A61M 15/08 A61M 15/085 A24F 47/00 A24F 47/002 A24F 47/004 A24F 47/008 A24F 40/00 A24F 40/30 A61K 31/35 A61K 9/008 A61P 29/02
Filing Date
2023-10-12
Application No.
18379189
Claims
17
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.